Literature DB >> 29155026

Personalized nanomedicine for CNS diseases.

Ajeet Kaushik1, Rahul Dev Jayant1, Vinay Bhardwaj2, Madhavan Nair3.   

Abstract

Central nervous system (CNS) diseases are rapidly increasing globally. Currently used therapeutic agents to treat CNS diseases exhibit significant efficacy. However, the inability of these drugs to cross the blood-brain barrier (BBB) and invasiveness of the technologies to achieve localized drug delivery in disease-specific parts of the brain have thwarted pain-free and complete treatment of CNS diseases. Therefore, the safe, non-invasive, and targeted delivery of drugs to the brain using nanoparticles (NPs) is currently receiving considerable research attention. Here, we highlight advances in state-of-the-art personalized nanomedicine for the treatment of CNS diseases (with a focus on dementia), the related challenges, possible solutions, and prospects for nano-enabled personalized medicine.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Mesh：

Year:  2017        PMID： 29155026      PMCID： PMC6897362          DOI： 10.1016/j.drudis.2017.11.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  61 in total

1.  HIV-associated dementia: an inconvenient truth.

Authors:  Bruce James Brew; Francisco González-Scarano
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

2.  An effective novel delivery strategy of rasagiline for Parkinson's disease.

Authors:  Marcos Fernández; Sofía Negro; Karla Slowing; Ana Fernández-Carballido; Emilia Barcia
Journal:  Int J Pharm       Date:  2011-07-22       Impact factor: 5.875

3.  Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression.

Authors:  Dou Yu; Omar F Khan; Mario L Suvà; Biqin Dong; Wojciech K Panek; Ting Xiao; Meijing Wu; Yu Han; Atique U Ahmed; Irina V Balyasnikova; Hao F Zhang; Cheng Sun; Robert Langer; Daniel G Anderson; Maciej S Lesniak
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 4.  Personalized nanomedicine.

Authors:  Twan Lammers; Larissa Y Rizzo; Gert Storm; Fabian Kiessling
Journal:  Clin Cancer Res       Date:  2012-07-24       Impact factor: 12.531

5.  Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes.

Authors:  Ioannis S Vizirianakis
Journal:  Nanomedicine       Date:  2010-11-19       Impact factor: 5.307

6.  Treatment of Parkinson's disease: nanostructured sol-gel silica-dopamine reservoirs for controlled drug release in the central nervous system.

Authors:  Tessy López; José L Bata-García; Dulce Esquivel; Emma Ortiz-Islas; Richard Gonzalez; Jorge Ascencio; Patricia Quintana; Gerko Oskam; Fernando J Alvarez-Cervera; Francisco J Heredia-López; José L Góngora-Alfaro
Journal:  Int J Nanomedicine       Date:  2010-12-16

7.  Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.

Authors:  Enara Herrán; Catalina Requejo; Jose Angel Ruiz-Ortega; Asier Aristieta; Manoli Igartua; Harkaitz Bengoetxea; Luisa Ugedo; Jose Luis Pedraz; Jose Vicente Lafuente; Rosa Maria Hernández
Journal:  Int J Nanomedicine       Date:  2014-05-27

8.  Investigation of ac-magnetic field stimulated nanoelectroporation of magneto-electric nano-drug-carrier inside CNS cells.

Authors:  Ajeet Kaushik; Roozbeh Nikkhah-Moshaie; Raju Sinha; Vinay Bhardwaj; Venkata Atluri; Rahul Dev Jayant; Adriana Yndart; Babak Kateb; Nezih Pala; Madhavan Nair
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

9.  Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease.

Authors:  Adina N Lazar; Spyridon Mourtas; Ihsen Youssef; Christophe Parizot; Aurélien Dauphin; Benoît Delatour; Sophia G Antimisiaris; Charles Duyckaerts
Journal:  Nanomedicine       Date:  2012-12-07       Impact factor: 5.307

Review 10.  Targeting delivery in Parkinson's disease.

Authors:  Ben Newland; Stephen B Dunnett; Eilís Dowd
Journal:  Drug Discov Today       Date:  2016-06-14       Impact factor: 7.851
View more
  10 in total

1.  Toxicological Aspects of Iron Oxide Nanoparticles.

Authors:  Natalia Fernández-Bertólez; Carla Costa; Fátima Brandão; João Paulo Teixeira; Eduardo Pásaro; Vanessa Valdiglesias; Blanca Laffon
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Improved Pharmacodynamic Potential of Rosuvastatin by Self-Nanoemulsifying Drug Delivery System: An in vitro and in vivo Evaluation.

Authors:  Ravinder Verma; Ajeet Kaushik; Rafa Almeer; Md Habibur Rahman; Mohamed M Abdel-Daim; Deepak Kaushik
Journal:  Int J Nanomedicine       Date:  2021-02-09

3.  Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection.

Authors:  Ajeet Kaushik; Adriana Yndart; Venkata Atluri; Sneham Tiwari; Asahi Tomitaka; Purnima Gupta; Rahul Dev Jayant; David Alvarez-Carbonell; Kamel Khalili; Madhavan Nair
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

Review 4.  In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.

Authors:  Sounak Bagchi; Tanya Chhibber; Behnaz Lahooti; Angela Verma; Vivek Borse; Rahul Dev Jayant
Journal:  Drug Des Devel Ther       Date:  2019-10-18       Impact factor: 4.162

Review 5.  COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications.

Authors:  Vicky Yamamoto; Joe F Bolanos; John Fiallos; Susanne E Strand; Kevin Morris; Sanam Shahrokhinia; Tim R Cushing; Lawrence Hopp; Ambooj Tiwari; Robert Hariri; Rick Sokolov; Christopher Wheeler; Ajeet Kaushik; Ashraf Elsayegh; Dawn Eliashiv; Rebecca Hedrick; Behrouz Jafari; J Patrick Johnson; Mehran Khorsandi; Nestor Gonzalez; Guita Balakhani; Shouri Lahiri; Kazem Ghavidel; Marco Amaya; Harry Kloor; Namath Hussain; Edmund Huang; Jason Cormier; J Wesson Ashford; Jeffrey C Wang; Shadi Yaghobian; Payman Khorrami; Bahman Shamloo; Charles Moon; Payam Shadi; Babak Kateb
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Retroviral infection of human neurospheres and use of stem Cell EVs to repair cellular damage.

Authors:  Heather Branscome; Pooja Khatkar; Sarah Al Sharif; Dezhong Yin; Sheela Jacob; Maria Cowen; Yuriy Kim; James Erickson; Christine A Brantner; Nazira El-Hage; Lance A Liotta; Fatah Kashanchi
Journal:  Sci Rep       Date:  2022-02-07       Impact factor: 4.379

Review 7.  Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.

Authors:  Raj Kumar; Piyush Mehta; Konathala Ravi Shankar; Manju A K Rajora; Yogendra Kumar Mishra; Ebrahim Mostafavi; Ajeet Kaushik
Journal:  Pharm Res       Date:  2022-05-12       Impact factor: 4.580

8.  QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics.

Authors:  Deepshi Arora; Shailendra Bhatt; Manish Kumar; Ravinder Verma; Yugam Taneja; Nikita Kaushal; Abhishek Tiwari; Varsha Tiwari; Athanasios Alexiou; Sarah Albogami; Saqer S Alotaibi; Vineet Mittal; Rajeev K Singla; Deepak Kaushik; Gaber El-Saber Batiha
Journal:  Front Aging Neurosci       Date:  2022-08-11       Impact factor: 5.702

Review 9.  Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go.

Authors:  Pragya Prasanna; Arun Upadhyay
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-27

10.  The Mast Cell Is an Early Activator of Lipopolysaccharide-Induced Neuroinflammation and Blood-Brain Barrier Dysfunction in the Hippocampus.

Authors:  Huanhuan Sha; Leting Zhou; Yiwei Wang; Yinan Chen; Qin Zhou; Hongquan Dong; Yanning Qian
Journal:  Mediators Inflamm       Date:  2020-02-24       Impact factor: 4.711
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.